PARP Inhibitors

The present Competitive Intelligence Report about PARP Inhibitors provides a competitor evaluation in the field of investigational small molecules inhibiting poly-adenyl-ribose polymerase (PARP) for treatment of cancer as of April 2009.

Poly (ADP-ribose) polymerases (PARPs) are a family of nuclear enzymes implicated in the regulation of multiple physiological cellular functions, including DNA repair, gene transcription, protein modification and cell signaling. Over-activation of PARP results in pathologic alteration of cellular metabolism, activation of inflammatory pathways, perturbation of cellular energetics, and cell death through necrosis or apoptosis. Because of its involvement in DNA repair, PARP has been implicated in the development of anti-tumor drug resistance. Targeting PARP is an approach in solid tumor therapy for potentiating the effects of chemotherapy and of radiation therapy and for potentially reducing antitumor drug resistance or resensitizing resistant patients to antitumor therapies. The most advanced projects are in phase II studies of solid tumors.

The report includes a compilation of current active projects in research and development of PARP targeting small molecules. In addition, the report lists company-specific R&D pipelines of EpCAM Antagonists. Competitor projects are listed in a tabular format providing information on:

- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.